Current Drug Development Status for Stroke

Although drug development and clinical trials for stroke have never stopped and many potential stroke therapeutic targets and potential drugs have been identified (see table below), no effective treatment or prevention of stroke has been established, and progress in targeted drug research has been unsatisfactory. In addition, the blood-brain barrier is a major challenge impeding stroke drug development. The only widely used stroke therapy is reperfusion with recombinant tissue plasminogen activator (rtPA), but due to contraindications, only about 10% of patients can receive this therapy. The more research directions there are, the better the chances of successful stroke therapy development. For different therapies, Ace Therapeutics offers different drug development services and corresponding testing components to meet each of your needs.

Current Drug Development Status for Stroke

Targeted new drug development is a traditional and important part of drug discovery. As stroke has been intensively studied, more and more targets have been identified. Therefore, it is critical to develop new drugs for stroke targets. Ace Therapeutics continues to update and develop its technology library as it evolves with the times. We now have a comprehensive range of targeted drug development technologies. From target validation to safety evaluation, we have a group of professional scientists to provide you with one-stop scientific services to accelerate the development of your targeted stroke drugs.

  • Target identification & validation
  • Candidate identification
  • Candidate optimization
  • Pharmacological evaluation
  • Safety evaluation

As stem cell therapies for stroke have been intensively researched, their therapeutic effects have become more evident, which offers new hope for the treatment of subacute and chronic strokes. Stem cell therapy is mainly used to relieve stroke through two pathways: neuroregeneration and neuroprotection. The former can reduce neuronal damage caused by stroke or even replace damaged neurons, while the latter works in the acute phase of a stroke to limit the spread of damage. In addition, stem cell therapy can further prevent the progression of stroke by modulating neurogenesis, angiogenesis, neuroinflammation, and apoptosis. Although stem cell therapy for stroke is very promising, there are still many challenges such as drug delivery methods and toxicology studies.

Ace Therapeutics provides the technology for the development of stem cell therapies for stroke. We have excellent scientists who have been working on stem cell therapies for decades and have established a mature and stable workflow to help you accelerate your research on the development of stem cell therapies for stroke.

Despite the fact that stroke attacks can disrupt the blood-brain barrier, the blood-brain barrier has been a roadblock to stroke drug development, leading to the failure of many potential drug translations. Current solutions to the blood-brain barrier are focused on exploring new drug delivery routes. An ideal drug delivery system that can penetrate the blood-brain barrier generally has characteristics such as release controllability, no damage to the BBB, biodegradability, and brain-targeting. The nanotechnology-based drug delivery system, liposomal drug delivery systems, and exosomal drug delivery systems are some of the common routes used for stroke drug delivery. These approaches can effectively modify pharmacokinetic behavior, improve targeted delivery or minimize side effects.

To address the issue of blood-brain barrier permeability, Ace Therapeutics provides services related to blood-brain barrier permeability testing, drug candidate structure optimization, and drug delivery systems. We work tirelessly to accelerate your stroke drug development.

There are also many common treatments for stroke such as antiplatelet therapy, antioxidants, neuroprotection, neurorepair, etc. All of these pathways lay the foundation for an early attack on stroke. You can find a variety of preclinical research services related to stroke on this website, and please feel free to contact us with any questions you may have.

  1. Barthels, D.Das, H., Current advances in ischemic stroke research and therapies. Biochim Biophys Acta Mol Basis Dis, 2020. 1866(4): p. 165260.
  2. Paul, S.Candelario-Jalil, E., Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol, 2021. 335: p. 113518.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Inquiry Basket